Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Article
PubMed
Google Scholar
Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.
Article
CAS
PubMed
Google Scholar
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD, et al. Somatic mutations in brca1 and brca2 could expand the number of patients that benefit from poly (adp ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–6.
Article
PubMed
PubMed Central
Google Scholar
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of brca mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene brca1. Science. 1994;266:66–71.
Article
CAS
PubMed
Google Scholar
Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73:2025–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of brca1 and brca2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71–80.
Article
CAS
PubMed
Google Scholar
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene brca2. Nature. 1995;378:789–92.
Article
CAS
PubMed
Google Scholar
Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8.
Article
CAS
PubMed
Google Scholar
Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of brca1 function in a defined tumor cell line. Mol Cell. 1999;4:1093–9.
Article
CAS
PubMed
Google Scholar
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(adp-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15.
Article
CAS
PubMed
Google Scholar
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among brca1 and brca2 carriers. Breast Cancer Res. 2009;11:R76.
Article
PubMed
PubMed Central
Google Scholar
Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral igf-i protein expression is selectively upregulated in breast cancer patients with brca1/2 mutations. Endocr Relat Cancer. 2007;14:1053–62.
Article
CAS
PubMed
Google Scholar
Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-i receptor (igf-ir) levels in primary breast tumors associated with brca1 mutations. Cancer Lett. 2007;257:236–43.
Article
CAS
PubMed
Google Scholar
Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, et al. Serum levels of igf-i and brca penetrance: A case control study in breast cancer families. Fam Cancer. 2011;10:521–8.
Article
CAS
PubMed
Google Scholar
Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, et al. Identification of insulin and insulin-like growth factor i (igf i) receptors in ovarian cancer tissue. Gynecol Oncol. 1994;53:196–201.
Article
CAS
PubMed
Google Scholar
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, et al. Igf-i in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007;25:346–54.
Article
CAS
PubMed
Google Scholar
Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-i (igf-i) and igf-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;78:271–6.
CAS
PubMed
Google Scholar
Weigang B, Nap M, Bittl A, Jaeger W. Immunohistochemical localization of insulin-like growth factor 1 receptors in benign and malignant tissues of the female genital tract. Tumour Biol. 1994;15:236–46.
Article
CAS
PubMed
Google Scholar
Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor i, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991;51:5107–12.
CAS
PubMed
Google Scholar
Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43.
Article
PubMed
PubMed Central
Google Scholar
Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor i targeting in epithelial ovarian cancer. Gynecol Oncol. 2006;100:389–96.
Article
CAS
PubMed
Google Scholar
Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest. 1993;69:756–60.
CAS
PubMed
Google Scholar
Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, et al. Bms-536924 sensitizes human epithelial ovarian cancer cells to the parp inhibitor, 3-aminobenzamide. Gynecol Oncol. 2009;115:193–8.
Article
CAS
PubMed
Google Scholar
Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010;2010:257058.
Article
PubMed
PubMed Central
Google Scholar
An Y, Cai Y, Guan Y, Cai L, Yang Y, Feng X, et al. Inhibitory effect of small interfering rna targeting insulin-like growth factor-i receptor in ovarian cancer ovcar3 cells. Cancer Biother Radiopharm. 2010;25:545–52.
Article
CAS
PubMed
Google Scholar
27 Hartog H, Boezen HM, de Jong MM, Schaapveld M, Wesseling J, van der Graaf WT. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast (Edinburgh, Scotland) 2013;22:1155–1160.
28 Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia (New York, NY) 2011;13:504–515.
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type i insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010;29:251–62.
Article
CAS
PubMed
Google Scholar
Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, et al. Inhibition of type i insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS ONE. 2013;8:e73406.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29:2517–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM. Igf-1r inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene. 2013.
Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett. 2005;222:173–81.
Article
CAS
PubMed
Google Scholar
Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. Brca1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006;66:41–5.
Article
CAS
PubMed
Google Scholar
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. Brca1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious brca1 mutation. Mol Oncol. 2013;7:567–79.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. Pi3k inhibition impairs brca1/2 expression and sensitizes brca-proficient triple-negative breast cancer to parp inhibition. Cancer Discovery. 2012;2:1036–47.
Article
CAS
PubMed
Google Scholar
Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, et al. Insulin-like growth factor-i controls brca1 gene expression through activation of transcription factor sp1. Horm Metab Res. 2007;39:179–85.
Article
CAS
PubMed
Google Scholar
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
Article
CAS
PubMed
Google Scholar
Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70:440–6.
Article
CAS
PubMed
Google Scholar
RL OD, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE. 2014;9:e90604.
Article
Google Scholar
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med. 2009;361:123–34.
Article
CAS
PubMed
Google Scholar
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in brca1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet. 1995;56:265–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of brca1 and brca2 among ashkenazi jews. N Engl J Med. 1997;336:1401–8.
Article
CAS
PubMed
Google Scholar
Chen S, Parmigiani G. Meta-analysis of brca1 and brca2 penetrance. J Clin Oncol. 2007;25:1329–33.
Article
PubMed
PubMed Central
Google Scholar
Abramovitch S, Glaser T, Ouchi T, Werner H. Brca1-sp1 interactions in transcriptional regulation of the igf-ir gene. FEBS Lett. 2003;541:149–54.
Article
CAS
PubMed
Google Scholar
Amichay K, Kidron D, Attias-Geva Z, Schayek H, Sarfstein R, Fishman A, et al. Brca1 is expressed in uterine serous carcinoma (usc) and controls insulin-like growth factor i receptor (igf-ir) gene expression in usc cell lines. Int J Gynecol Cancer. 2012;22:748–54.
Article
PubMed
Google Scholar
Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, et al. P53 regulates insulin-like growth factor-i receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-i receptor-directed targeted therapy. Eur J Cancer. 2012;48:1570–80.
Article
CAS
PubMed
Google Scholar
Shukla V, Coumoul X, Cao L, Wang RH, Xiao C, Xu X, et al. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res. 2006;66:7151–7.
Article
CAS
PubMed
Google Scholar
Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM. Suppression of homologous recombination sensitizes human tumor cells to igf-1r inhibition. Int J Cancer. 2015;136(12):2961–6. doi:10.1002/ijc.29327.
Article
CAS
PubMed
Google Scholar
Chen HX, Sharon E. Igf-1r as an anti-cancer target--trials and tribulations. Chin J Cancer. 2013;32:242–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (cp-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009;4:1397–403.
Article
PubMed
PubMed Central
Google Scholar
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P. Meijers M, et al. Clin Cancer Res: Functional ex vivo assay to select homologous recombination deficient breast tumors for parp inhibitor treatment; 2014.
Google Scholar
Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, et al. Role of the insulin-like growth factor i/insulin receptor substrate 1 axis in rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol. 2003;23:7510–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P, Shi CH, et al. Inhibition of both egfr and igf1r sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair. PLoS ONE. 2013;8:e68784.
Article
CAS
PubMed
PubMed Central
Google Scholar
Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, et al. Depletion of the type 1 igf receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol. 2012;103:402–9.
Article
CAS
PubMed
Google Scholar